Benedetta Conte, IDIBAPS, Barcelona, Spain, shares highlights from the European Society of Medical Oncology (ESMO) Breast Cancer 2022 meeting, including on novel antibody drug conjugates (ADCs) for the treatment across various breast cancer subtypes, HR-positive, HER2-posistve and triple-negative breast cancer (TNBC). Benedetta Conte also brings to attention the Phase I TOT-HER3 (NCT04752059) trial, the Phase II TUXEDO-1 (NCT04752059) trial and the Phase III, MONALEESA-3 (NCT02422615) and PADA-1 (NCT03079011) trials. The TUXEDO-1 and TOT-HER3 clinical studies demonstrated promising results for ADCs in breast cancer, and the Phase III MONALEESA study showed an impressive overall- survival rate of 71 months with the treatment of ribociclib plus fulvestrant in postmenopausal advanced breast cancer. The Phase III PANDA-1 investigated the role of liquid biopsies in the metastatic HR+ breast cancer setting. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.